Metoprolol Succinate
Rank #75 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$256.3M
Total Cost
12,847,535
Total Claims
$256.3M
Total Cost
122,722
Prescribers
$20
Cost per Claim
3,761,958
Beneficiaries
30,631,695
30-Day Fills
$2,088
Avg Cost/Provider
105
Avg Claims/Provider
Share of Medicare Part D Spending
0.09%
of total Medicare Part D spending
$256.3M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $256.3M total
Top Prescribers of Metoprolol Succinate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Don Lee | Interventional Cardiology | Glendale, CA | 3,555 | $73K |
| 2 | Humberto Machado | Cardiology | Coral Gables, FL | 3,503 | $63K |
| 3 | Prakash Shah | Cardiology | Milwaukee, WI | 3,422 | $62K |
| 4 | Minping Liu | Internal Medicine | Boston, MA | 1,812 | $53K |
| 5 | Zoheir Abdelbaki | Cardiology | Lima, OH | 2,345 | $51K |
| 6 | Mark Desnoyers | Cardiology | North Dartmouth, MA | 1,782 | $47K |
| 7 | Hazar Dahhan | Cardiology | Manchester, CT | 2,123 | $47K |
| 8 | Michael Robertello | Cardiology | Rutland, VT | 1,825 | $47K |
| 9 | Marilyn Cox | Clinical Cardiac Electrophysiology | Tallahassee, FL | 1,754 | $45K |
| 10 | Kenneth Wong | Cardiology | Raceland, LA | 2,353 | $43K |
| 11 | Thomas Mcgarry | Interventional Cardiology | Oklahoma City, OK | 1,804 | $43K |
| 12 | Matthew Graziano | Physician Assistant | Orchard Park, NY | 1,449 | $42K |
| 13 | M Sharif | Cardiology | Lubbock, TX | 2,207 | $41K |
| 14 | Andrew Graf | Internal Medicine | Plymouth Meeting, PA | 3,023 | $40K |
| 15 | Randeep Suneja | Cardiology | Katy, TX | 1,995 | $40K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 72 | Risankizumab-Rzaa (Skyrizi Pen) | $259.7M | 12,539 |
| 73 | Venetoclax (Venclexta) | $259.6M | 28,191 |
| 74 | Zanubrutinib (Brukinsa) | $256.8M | 19,239 |
| 75 | Metoprolol Succinate (Metoprolol Succinate) | $256.3M | 12,847,535 |
| 76 | Dolutegravir Sodium (Tivicay) | $251.7M | 102,995 |
| 77 | Abemaciclib (Verzenio) | $242.2M | 16,125 |
| 78 | Abacavir/Dolutegravir/Lamivudi (Triumeq) | $238.1M | 61,147 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology